Announcements Trials
Browse Landscape

Phase

Phase NA 15Phase 4 3Phase 2 3Phase 3 1Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 91Neoplasms 75Prostatic Neoplasms 54Carcinoma, Hepatocellular 53Colorectal Neoplasms 49Leukemia, Myeloid, Acute 41Stomach Neoplasms 36Carcinoma, Non-Small-Cell Lung 36Precursor Cell Lymphoblastic Leukemia-Lymphoma 34Neoplasm Metastasis 29Pancreatic Neoplasms 27Lung Neoplasms 26Rectal Neoplasms 23Multiple Myeloma 21Hematologic Neoplasms 21Head and Neck Neoplasms 20Colonic Neoplasms 20Recurrence 19Lymphoma 19Leukemia 19Polycystic Ovary Syndrome 16Liver Neoplasms 14Esophageal Neoplasms 14Brain Neoplasms 13Myelodysplastic Syndromes 12Melanoma 12Endometrial Neoplasms 12Uterine Cervical Neoplasms 11Motor Activity 11Fatigue 11

Interventions

Therapeutics 1Olanzapine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × OTHER × Postoperative Nausea and Vomiting × Clear all
NCT03631004 2022-01-13

Pre-operative Olanzapine as Prophylactic Antiemetic in Oncologic Patients

Instituto do Cancer do Estado de São Paulo

Phase 2/3 Completed
100 enrolled

Nausea, Vomiting, Postoperative Nausea and Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡